Drug Profile
Amphotericin B oral - iCo Therapeutics
Alternative Names: iCo-009; iCo-010; iCo-019; Oral AmpB; Oral AmpB delivery system; Oral amphotericin B delivery systemLatest Information Update: 28 Jan 2023
Price :
$50
*
At a glance
- Originator University of British Columbia
- Developer iCo Therapeutics
- Class Antifungals; Antiprotozoals; Macrolides
- Mechanism of Action Cell membrane permeability enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported HIV-1 infections; Mycoses; Visceral leishmaniasis
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for phase-I development in Mycoses(In volunteers) in Australia (PO, Capsule)
- 13 Jul 2020 Adverse events data from a phase 1b trial in Mycoses (In volunteers) released by iCo Therapeutics
- 15 Apr 2020 Pharmacokinetics and adverse events data from a phase Ib trial in Mycoses (In volunteers) released by iCo Therapeutics